This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Ritchey AK, Land V, Steuber CP, Weinstein H . Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML study 8498 Blood 1992 80: 2210–2214
Lie SO, Jonmundsson G, Mellander L, Siimes M, Yssing M, Gustafsson G . A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants and children with Down's syndrome Br J Haematol 1996 94: 82–88
Dördelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, Lampert F, Harbott J, Niemeyer C, Ritter J, Dörffel W, Nessler G, Kuhl J, Riehm H . Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials Leukemia 1998 12: 645–651
Glomstein A, Gustafsson G, Clausen N, Saarinen-Pihkala UM, Lie SO . Down's syndrome and acute leukemia in children: a population-based Nordic study Med Ped Oncol 1999 33: 245
Gustafsson G, Kreuger A, Clausen N, Garwicz S, Kristinsson J, Lie SO, Moe PJ, Perkkiö M, Yssing M, Saarinen-Pihkala UM . Intensified treatment of acute childhood lymphoblastic leukemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 to 1996 Acta Paediatr 1998 87: 1151–1161
Kaspers GJL, Veerman AJP, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, Van Der Does-Van Den Berg A . In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia Blood 1998 90: 2723–2729
Nygren P, Kristensen J, Jonsson B, Sundström C, Lönnerholm G, Kreuger A, Larsson R . Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia Leukemia 1992 6: 1121–1128
Taub JW, Stout ML, Buck SA, Huang X, Vega RA, Becton DL, Ravindranath Y . Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin Leukemia 1997 11: 1594–1595
Kaspers GJL, Zwaan CM, Ramakers-Van Woerden NL, Pieters R, Wunsche R, Rottier MMA, Hählen K, Janka-Schaub G, Creutzig U, Veerman AJP . Favorable in vitro drug resistance profiles in children with Down syndrome and acute leukemia, both in ALL and AML ASH, Miami 1998 abstr. 1642
Acknowledgements
This work was supported by Lions’ Cancer Research Foundation in Uppsala and by the Children's Cancer Foundation in Sweden. The contribution of patient samples from members of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) is gratefully acknowledged.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Frost, BM., Gustafsson, G., Larsson, R. et al. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?. Leukemia 14, 943–944 (2000). https://doi.org/10.1038/sj.leu.2401753
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401753
This article is cited by
-
Clinical and biological aspects of myeloid leukemia in Down syndrome
Leukemia (2021)
-
Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children’s Cancer Study Group and the Kyushu Yamaguchi Children’s Cancer Study Group
International Journal of Hematology (2011)
-
Ontwikkelingen in de diagnostiek en behandeling van leukemie bij kinderen met downsyndroom
Tijdschrift voor Kindergeneeskunde (2009)
-
The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy
Leukemia (2008)
-
Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature
Annals of Hematology (2006)